Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine, Atlanta, Ga.
Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine, Atlanta, Ga.
J Thorac Cardiovasc Surg. 2019 Dec;158(6):1516-1524. doi: 10.1016/j.jtcvs.2019.01.116. Epub 2019 Feb 11.
Acute type A dissection with mesenteric malperfusion is a rare but lethal variant of aortic dissection. This study examines outcomes from various treatment algorithms.
A review from 2003 to 2017 of the Emory Aortic Database identified 34 patients who presented with acute type A dissection with mesenteric malperfusion. Outcomes from 4 different treatment strategies were analyzed: ascending aortic/arch replacement followed by laparotomy (n = 13), axillary-bifemoral artery bypass followed by ascending/arch replacement (n = 3); ascending/arch and concomitant antegrade thoracic endovascular aortic repair (TEVAR) (n = 5), and TEVAR followed by delayed ascending/arch replacement (TEVAR-1st) (n = 13).
The mean age of all patients was 53 ± 13 years and was equivalent among the groups. The incidence of concomitant renal and ileofemoral malperfusion was 52% and 41%, and the initial serum lactate level was 4.3 ± 2.1 mmol/L. Overall mortality was 55.8%. In the ascending aortic/arch replacement followed by laparotomy group, 77% of patients had postoperative bowel necrosis or intractable acidosis and the mortality was 69.2%. All patients in the axillary-bifemoral artery bypass followed by ascending/arch replacement group survived, but 66% required postoperative dialysis. In the ascending/arch and concomitant antegrade/TEVAR group, the mortality was 80% secondary to persistent postoperative bowel necrosis or intractable acidosis. Three patients in the TEVAR-1st group died before aortic replacement. In the 10 patients who underwent TEVAR followed by delayed aortic replacement, the mortality was 30%. There were no cases of postoperative bowel necrosis or intractable acidosis in the TEVAR-1st group.
The TEVAR-1st strategy delays central aortic replacement until end-organ ischemia has resolved. This novel paradigm serves as a bridge to decision, and may improve survival compared with conventional treatment strategies in acute type A dissection with mesenteric malperfusion.
合并肠系膜动脉灌注不良的急性 A 型主动脉夹层是一种罕见但致命的主动脉夹层变体。本研究探讨了各种治疗方案的结果。
对 2003 年至 2017 年期间埃默里主动脉数据库的回顾,确定了 34 名患有急性 A 型主动脉夹层合并肠系膜动脉灌注不良的患者。分析了 4 种不同治疗策略的结果:升主动脉/弓部置换后继以剖腹手术(n=13),腋股动脉旁路后继以升主动脉/弓部置换(n=3);升主动脉/弓部和同时顺行胸主动脉腔内修复术(TEVAR)(n=5),以及 TEVAR 后继以延迟升主动脉/弓部置换(TEVAR-1st)(n=13)。
所有患者的平均年龄为 53±13 岁,各组之间无差异。合并肾和髂股动脉灌注不良的发生率分别为 52%和 41%,初始血清乳酸水平为 4.3±2.1mmol/L。总死亡率为 55.8%。在升主动脉/弓部置换后继以剖腹手术组中,77%的患者术后出现肠坏死或顽固性酸中毒,死亡率为 69.2%。腋股动脉旁路后继以升主动脉/弓部置换组所有患者均存活,但 66%需要术后透析。在升主动脉/弓部和同时顺行/TEVAR 组中,死亡率为 80%,继发于持续性术后肠坏死或顽固性酸中毒。TEVAR-1st 组中有 3 例患者在主动脉置换前死亡。在 10 例行 TEVAR 后继以延迟主动脉置换的患者中,死亡率为 30%。TEVAR-1st 组无术后肠坏死或顽固性酸中毒发生。
TEVAR-1st 策略延迟了中心主动脉置换,直到终末器官缺血得到缓解。这种新的治疗模式是一种决策桥梁,与合并肠系膜动脉灌注不良的急性 A 型主动脉夹层的传统治疗策略相比,可能提高生存率。